Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.58 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828013 | 0.91 | NR1I2 (0.68) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL13937014 | 0.90 | NR1I2 (0.57) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL13841837 | 0.86 | NR1I2 (0.55) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL13940670 | 0.85 | NR1I2 (0.67) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL13937015 | 0.85 | NR1I2 (0.57) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL13940106 | 0.84 | NR1I2 (0.67) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL14435700 | 0.84 | NR1I2 (0.66) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL13940672 | 0.84 | NR1I2 (0.67) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL13936891 | 0.84 | NR1I2 (0.81) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL13940404 | 0.83 | NR1I2 (0.58) | NR1I2SCN9AKCNH2CYP3A4SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538102-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538102-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538102-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| WO-2008112851-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | SLC10A1, HAVCR2, OAT | NR1I2 158/4885SCN9A 3801/4885KCNH2 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.